Adamas Newsroom

Press Releases

Adamas Pharmaceuticals Announces Issuance of First US Patent for Nurelin™ (Amantadine HCL Extended Release) Program — April 22, 2013
Adamas Pharmaceuticals Presents New Traumatic Brain Injury Data from its Nurelin™ Program at American Academy of Neurology Conference — March 20, 2013
Forest Laboratories and Adamas Pharmaceuticals Enter into Licensing Agreement for the Development and Commercialization of a Fixed Dosed Combination of Namenda XR® and Donepezil for Alzheimer’s Disease — November 13, 2012
Adamas Pharmaceuticals Presents Update On Nurelin^TM Program At Cambridge Healthtech Institute’s Parkinson’s Conference — June 4, 2012

© 2013 Adamas Pharmaceuticals, Inc.